Search PubMed⌕ Search

Biomedical subjects

D C Wheeler

Publications and source records attributed to D C Wheeler.

59 records · Page 4Linked to original sources
PubMed1984

Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping.

In a pilot study two patients with brittle asthma and two with morning dipping received terbutaline or a placebo administered subcutaneously either by continuous infusion or in injections every six hours. In two patients brittle asthma was completely suppressed by terbutaline 1 mg/day given by either method. In the two others early morning dipping responded only to continuous subcutaneous infusions of terbutaline 12 mg/day. Terbutaline administered subcutaneously may be an effective treatment in asthmatic patients who show important diurnal variations in air flow.

Adult↗
PubMed1980

Audiometric configuration in patients being treated for alcoholism.

The auditory acuity of 52 alcoholic subjects showed a consistent bilateral high frequency loss. Presence of this loss was found to be related to drinking time, but independent of age, suggesting a definite relationship between length of heavy drinking time and loss of auditory acuity in the high frequencies.

Adult↗
PubMedDate not supplied

Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.

Hyperlipidaemia complicating the nephrotic syndrome is characterised by elevated levels of total and LDL cholesterol, often with hypertriglyceridaemia and low HDL cholesterol levels. The underlying mechanisms are complex but involve abnormalities of both lipoprotein synthesis and catabolism. Experience to date suggests that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or "statins" offer the most effective therapy and are relatively safe, at least in short term studies. The benefits of treatment remain unproven but may include a reduction in cardiovascular risk and preservation of residual renal function. Newly defined actions of statins, some of which may be unrelated to lipid lowering, are likely to extend the application of these drugs in patients with glomerular disease.

Animals↗